23 June 2022
- 13:0613:06, 23 June 2022 diff hist 0 N File:Image8-ebafa5124d8196802324f40aa657b1d6.png No edit summary current
- 13:0613:06, 23 June 2022 diff hist 0 N File:Image7-5c82f9d4103405c86b2901b357f8d53e.png No edit summary current
- 13:0613:06, 23 June 2022 diff hist 0 N File:Image6-c6dd0fbb760921c68274a02aac6607ec.png No edit summary current
- 13:0613:06, 23 June 2022 diff hist 0 N File:Image5-e82b789cadf89720d0020af2ea338683.png No edit summary current
- 13:0613:06, 23 June 2022 diff hist 0 N File:Image4-666e5cc13984687522afaf3577c161a8.png No edit summary current
- 13:0513:05, 23 June 2022 diff hist 0 N File:Image3-9589bf31951e17ab949784badc9e0c4c.png No edit summary current
- 13:0513:05, 23 June 2022 diff hist +458 EQS Group →Summary Tag: Visual edit
- 12:5712:57, 23 June 2022 diff hist +35 EQS Group No edit summary
- 12:5512:55, 23 June 2022 diff hist 0 N File:EQS Group logo.jpg No edit summary current
- 12:5512:55, 23 June 2022 diff hist +16 EQS Group →Management team
- 12:5412:54, 23 June 2022 diff hist +1,523 EQS Group No edit summary Tag: Visual edit
- 01:1401:14, 23 June 2022 diff hist +40,644 N EQS Group Created page with "EQS is in a strong position to build its client base as the EU whistleblowing directive comes into force across Europe. Delays in adoption of formal legislation are a frustration but do not detract from the strength of the underlying proposition. EQS retains its ambition to be the leading European cloud provider for global investor relations and corporate compliance solutions by 2025. The €45m raised in March will help fund the repayment of short-term bank and vendor l..." Tag: Visual edit
22 June 2022
- 21:5621:56, 22 June 2022 diff hist +64 Scandion Oncology →Drug-resistance mechanisms are commonly reported Tag: Visual edit
- 16:2116:21, 22 June 2022 diff hist +87 Scandion Oncology No edit summary
- 16:1916:19, 22 June 2022 diff hist 0 N File:Scandion Oncology.jpeg No edit summary current
- 16:1716:17, 22 June 2022 diff hist +39 Scandion Oncology No edit summary
- 16:1416:14, 22 June 2022 diff hist +204 Scandion Oncology →Two shots on goal for SCO-101 Tag: Visual edit
- 16:1016:10, 22 June 2022 diff hist +104 Scandion Oncology →Further studies will require fresh capital Tag: Visual edit
- 16:0616:06, 22 June 2022 diff hist 0 N File:Image3-f037ec1ee2495554a573c0cdde896311.png No edit summary current
- 16:0616:06, 22 June 2022 diff hist 0 N File:Image4-6ff227f569067ae2b29573f4aa4f3314.png No edit summary current
- 16:0616:06, 22 June 2022 diff hist 0 N File:Image5-ca177f6ef17ee0c8dfa1ecbf0e399de9.png No edit summary current
- 16:0616:06, 22 June 2022 diff hist 0 N File:Image6-b18deb263878259b652ac43cea6d3088.png No edit summary current
- 16:0516:05, 22 June 2022 diff hist 0 N File:Image7-c31e427382287da7a43068acd0e06507.png No edit summary current
- 16:0516:05, 22 June 2022 diff hist 0 N File:Image8-d2f0ab9ac32701491636345b4497b7bb.png No edit summary current
- 15:0715:07, 22 June 2022 diff hist +6,948 Scandion Oncology →Summary Tag: Visual edit
- 14:1314:13, 22 June 2022 diff hist +79 Tesla, Inc. →Automotive sales Tag: Visual edit
- 14:1114:11, 22 June 2022 diff hist +8,410 Tesla, Inc. →Automotive sales
- 14:1114:11, 22 June 2022 diff hist −8,411 Tesla, Inc. →Automotive
- 14:0514:05, 22 June 2022 diff hist −9 Tesla, Inc. →Energy generation and storage sales Tag: Visual edit
- 14:0114:01, 22 June 2022 diff hist −8 Tesla, Inc. →Energy generation and storage sales Tag: Visual edit
- 13:3613:36, 22 June 2022 diff hist +2 Tesla, Inc. →Energy generation and storage sales Tag: Visual edit
- 13:3413:34, 22 June 2022 diff hist +410 Tesla, Inc. →Energy generation and storage sales Tag: Visual edit
- 13:0213:02, 22 June 2022 diff hist +2,660 Tesla, Inc. →Energy generation and storage sales Tag: Visual edit
21 June 2022
- 23:5023:50, 21 June 2022 diff hist +38,890 N Scandion Oncology Created page with "== Summary == '''Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance. Its lead asset, SCO-101, is being investigated as an add-on therapy to existing treatments in metastatic colorectal cancer (mCRC) and unresectable pancreatic cancer (PC). Management’s clinical programme is spearheaded by the Phase II CORIST study in FOLFIRI-resistant mCRC, from which we expect crucial proof-of-concept results in..." Tag: Visual edit
10 June 2022
- 19:3919:39, 10 June 2022 diff hist +150 Seraphim Space Investment Trust No edit summary Tag: Visual edit
- 19:3619:36, 10 June 2022 diff hist +6 Seraphim Space Investment Trust →Board: Complementary skills, a female majority and equal pay Tag: Visual edit
- 19:2919:29, 10 June 2022 diff hist +11 Seraphim Space Investment Trust →Risks and sensitivities
- 19:2919:29, 10 June 2022 diff hist +56 Seraphim Space Investment Trust →Premium/discount reflects scarcity, valuation policy, illiquidity and market volatility
- 19:2819:28, 10 June 2022 diff hist 0 N File:Volatile premium range since launch.png No edit summary current
- 19:2819:28, 10 June 2022 diff hist +84 Seraphim Space Investment Trust →Peer group comparison: A lone wolf
- 19:2719:27, 10 June 2022 diff hist 0 N File:Passive and listed strategies have failed to capture the growth.png No edit summary current
- 19:2719:27, 10 June 2022 diff hist +60 Seraphim Space Investment Trust →Performance: Very early days
- 19:2719:27, 10 June 2022 diff hist 0 N File:NAV and share price return since launch.png No edit summary current
- 19:2619:26, 10 June 2022 diff hist +52 Seraphim Space Investment Trust →Current portfolio positioning
- 19:2519:25, 10 June 2022 diff hist +65 Seraphim Space Investment Trust →Premium/discount reflects scarcity, valuation policy, illiquidity and market volatility
- 19:2519:25, 10 June 2022 diff hist 0 N File:SSIT portfolio at December 2021.png No edit summary current
- 19:2419:24, 10 June 2022 diff hist 0 N File:Quoted portfolio performance since July 2021.png No edit summary current
- 19:2319:23, 10 June 2022 diff hist +482 Seraphim Space Investment Trust →Space technology: Addressing a vast opportunity via technical innovation Tag: Visual edit
- 19:1919:19, 10 June 2022 diff hist +43,920 Seraphim Space Investment Trust No edit summary Tag: Visual edit
- 19:0219:02, 10 June 2022 diff hist +3,254 N Seraphim Space Investment Trust Created page with "Seraphim Space LLP (Seraphim Space), which manages the Seraphim Space Investment Trust (SSIT), believes the space technology market could grow 5–7x to c $2–3tn by 2035. Key drivers are the dramatic fall in the cost of launch, principally thanks to SpaceX, and a revolution in the satellite industry where technological developments originally pioneered within the smartphone and automotive industries have driven down the size, cost and weight of satellites while expandi..."
